Výsledky vyhledávání

Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)

Autor: Chau T. Dang, Renjing Wang, Diana Lake, J. Baselga, Valentina Sterlin, S Wong, Jasmeet Chadha Singh, M Goldstein, Larry Norton

Publikováno v: Cancer Research. 79:P6-18

Background: Neratinib (N) is a potent irreversible inhibitor of HER1, HER2, and HER4 and has been shown to have antitumor activity in patients (pts) with human epidermal growth factor receptor 2 (HER2) - positive breast cancer. A previous study of co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25e1433c516d09b8b329afb3e031ace9
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-30

Zobrazit plný text záznamu

Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses

Autor: T Garimella, Caleb Lee, Masahiro Sugihara, Junji Tsurutani, Ian E. Krop, Kazuo Tamura, J. Baselga, H. Iwata, Lin Zhang, O Yin, Antoine Yver, Russ Wada, Shanu Modi, S. Takahashi

Publikováno v: Cancer Research. 79:P6-17

Background DS-8201a is a HER2-targeting antibody-drug conjugate with a high drug-to-antibody ratio of 7 to 8. A novel cleavable peptide-based linker joins the humanized HER2 antibody to a topoisomerase I inhibitor payload. In an ongoing phase 1 study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aaa66583e57d97849982954abdce5f8
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-10

Zobrazit plný text záznamu

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

Publikováno v: Annals of Oncology
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

Altres ajuts: European Research Area-NET, Transcan-2 (AC15/00063), Asociación Española Contra el Cáncer (LABAE16020PORTT) i AIOC15152806CRUZ, Generalitat de Catalunya(PERIS, SLT002/16/00477 En el cas dels drets, per a usos comercials contactar amb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cac37072c81f83232b13085f5ef04dc
https://doi.org/10.1093/annonc/mdy099

Zobrazit plný text záznamu

Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer

Autor: R. D. Gelber, Emma Clark, Thomas M. Suter, Amal Arahmani, E. de Azambuja, Dimitrios Zardavas, J. Baselga, Marion Procter, Eleonora Restuccia, José Bines, Jennifer Eng-Wong, M.J. Piccart, V Van Dooren, G. Viale, G. von Minckwitz

Publikováno v: Cancer Research. 78:P1-13

Background Diarrhea is the most commonly reported adverse event (AE) on pertuzumab (Ptz) in both early and metastatic breast cancer (BC) settings. We report safety analyses of diarrhea from the large adjuvant APHINTY study in HER2 positive early brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4ac8e83679c8e498f4eb2f15b10f72de
https://doi.org/10.1158/1538-7445.sabcs17-p1-13-07

Zobrazit plný text záznamu

Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)

Autor: Marcos Vinicius Silva Oliveira, Amy V. Kapp, Wai Y. Chan, Steven Gendreau, Stina M. Singel, S-B Kim, Matthew Wongchenko, Rebecca Dent, Cristina Saura, Daniel J. Maslyar, J. Baselga

Publikováno v: Cancer Research. 78:P2-09

Background: The oral Akt inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/Akt pathway activation. In the placebo-controlled randomized phase II LOTUS trial (NCT02162719), adding IPAT to PAC as first-line therapy for metasta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e760b20a9714ef4d06fc480c75fb365
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-20

Zobrazit plný text záznamu

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Autor: M Maetens, Floriane Dupont, J Huober, Sherene Loi, M Ignatiadis, J. Baselga, Lajos Pusztai, Ian Bradbury, M. Izquierdo, Christos Sotiriou, Françoise Rothé, David Venet, M.J. Piccart, Debora Fumagalli, Paolo Nuciforo, Roberto Salgado, L de la Pena, E. de Azambuja, Nadia Harbeck

Publikováno v: Cancer Research. 78:P2-05

Background A-to-I RNA editing, a post-transcriptional modification of the RNA catalyzed by the ADAR family of enzymes, is emerging as a widespread phenomenon in breast cancer (BC). A-to-I RNA editing is more frequent in the highly repetitive Alu regi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59fc9545ade485eac741ae51c459e409
https://doi.org/10.1158/1538-7445.sabcs17-p2-05-04

Zobrazit plný text záznamu

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial

Autor: L de la Pena, Sherene Loi, David N Brown, J Huober, Ian Bradbury, Françoise Rothé, M Maetens, David Venet, J. Baselga, Debora Fumagalli, M Ignatiadis, E. de Azambuja, Nadia Harbeck, Severine Sarp, Paolo Nuciforo, Roberto Salgado, Lajos Pusztai, M.J. Piccart, Christos Sotiriou

Publikováno v: Cancer Research. 78:GS1-04

Background In the NeoALTTO trial, the combination of trastuzumab and lapatinib for the neoadjuvant treatment of HER2 positive early breast cancer patients (pts) nearly doubled the rate of pathological complete response (pCR) compared with either anti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2b83fcdff786a2a5f422fcff9b334b41
https://doi.org/10.1158/1538-7445.sabcs17-gs1-04

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání